Comparison of the effectiveness of neoadjuvant pembrolizumab versus placebo for improving the pCR rate in ER-positive/HER2-negative breast cancer is being performed in the phase 3 KEYNOTE-756 trial (NCT03725059). Here, ESR1 is linked to breast carcinoma.